The evaluation of Nesfatin-1 levels in patients with OSAS associated with metabolic syndrome.

Autor: Aksu O; Division of Endocrinology and Metabolism, Department of Internal Medicine, Faculty of Medicine, Suleyman Demirel University, School of medicine, 3200, Isparta, Turkey. droaksu@yahoo.com., Aydın B; Division of Endocrinology and Metabolism, Department of Internal Medicine, Faculty of Medicine, Suleyman Demirel University, School of medicine, 3200, Isparta, Turkey., Doguç DK; Department of Biochemistry, Faculty of Medicine, Suleyman Demirel University, Isparta, Turkey., Ilhan I; Department of Biochemistry, Faculty of Medicine, Suleyman Demirel University, Isparta, Turkey., Ozturk O; Department of Chest Disease, Faculty of Medicine, Suleyman Demirel University, Isparta, Turkey., Altuntas A; Division of Nephrology, Department of Internal Medicine, Faculty of Medicine, Suleyman Demirel University, Isparta, Turkey., Demirkan H; Division of Endocrinology and Metabolism, Department of Internal Medicine, Faculty of Medicine, Suleyman Demirel University, School of medicine, 3200, Isparta, Turkey., Koroglu BK; Division of Endocrinology and Metabolism, Department of Internal Medicine, Faculty of Medicine, Suleyman Demirel University, School of medicine, 3200, Isparta, Turkey., Tamer MN; Division of Endocrinology and Metabolism, Department of Internal Medicine, Faculty of Medicine, Suleyman Demirel University, School of medicine, 3200, Isparta, Turkey.
Jazyk: angličtina
Zdroj: Journal of endocrinological investigation [J Endocrinol Invest] 2015 Apr; Vol. 38 (4), pp. 463-9. Date of Electronic Publication: 2014 Nov 29.
DOI: 10.1007/s40618-014-0216-0
Abstrakt: Purpose: The association of obstructive sleep apnea syndrome (OSAS) and metabolic syndrome (MS) has been demonstrated in studies and in recent years; the effect of OSAS on insulin resistance independent of the level of obesity is being investigated. Nesfatin-1 is a newly defined 82 amino acid protein with a precursor molecule of NUCB2 (nucleobindin 2). Nesfatin-1 is not only essential in regulation of food ingestion but also important in regulation of some brain functions, autonomic regulation, stress, mental state, and paradoxical sleep. We aimed to evaluate the relationship between OSAS and MS and the MS dependent or independent effect of Nesfatin-1 on this relationship.
Methods: Patients admitted with clinical signs of OSAS are included. Patients are divided into three groups based on Apnea-Hypopnea Index (AHI) on Polysomnography (PSG) as mild, moderate, and severe OSAS. A total of 59 patients were included the control patients. Several OSAS parameters and laboratory findings which are and are not MS dependent are compared. Nesfatin-1 levels are evaluated in all OSAS patients with and without MS.
Results: There were significantly more males in all groups (p = 0.007). There was no significant difference between groups in terms of Nesfatin-1 levels. Nesfatin-1 levels were significantly lower in MS group compared to non-MS group (p = 0.021).
Conclusion: Nesfatin-1 which is known to play a role in the pathophysiology of insulin resistance can be a beneficial target in developing new therapeutic targets for treatment of patients with obesity without any toxic effects in the future.
Databáze: MEDLINE
Externí odkaz: